BioFIT 2023: The leading European partnering event in Life Sciences is back in Marseille
November 16, 2023 – Drug Discovery, Other, Pharmaceutical –
BioFIT, the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field, is set to take place on December 12th and 13th, 2023 in Marseille, France. This must-attend event brings together key stakeholders from academia, industry, and start-ups to foster partnerships and facilitate investment in the Life Sciences sector.
Fostering Innovation and Collaboration
BioFIT serves as a pivotal platform for driving innovation and accelerating partnerships in the Life Sciences, Biotechnology and Animal Health fields. Now in its 12th edition, BioFIT has established itself as a key event for professionals seeking to stay at the forefront of industry trends, explore collaboration opportunities, and showcase cutting-edge advancements.
BioFIT offers a dynamic meeting-place for participants to engage in a range of activities, including pre-arranged one-on-one meetings, high-level conferences, pitch sessions, and an exhibition area. By facilitating networking and collaborations, BioFIT creates an environment conducive to driving innovation and accelerating the development of promising projects in the Life Sciences industry.
Thanks to an online platform powered by Inpart, participants can pre-schedule meetings with key actors of the sector and identify potential partners to meet them during the event.
The conference programme revolves around the latest topics in the industry. Panel discussions will feature international experts sharing their experiences.
Innovative international organisations will present their project during this pitch competition in front of an expert jury. The winners will be awarded during the Award Ceremony.
Ideally located at the focal point of the event, it allows to explore a diverse range of products, technologies and services showcased by leading companies and start-ups in the Life Sciences sector.
A Conference Programme to Reflect on the Sector
The BioFIT conference programme is divided into four tracks in addition to the Plenary Session: best practices in R&D collaborations, nurturing and licensing early-stage assets, from seed to Series A: accessing early-stage investment and animal health highlights.
The plenary session will explore the impact of 2023 uncertainties on early-stage partnering strategies in the biopharma industry, including challenges and opportunities in financing and partnering. The panel will discuss effects on capital availability at seed and series A stages, emerging trends in early-stage collaborations, impacts on negotiation terms, and how biotech start-ups and pharma companies are adapting to the evolving landscape, with an outlook on Life Sciences dealmaking in 2024.
They Confirmed their Participation
AbbVie, AdBio partners, Andera Partners, Apollo Health Ventures, Bayer, Astellas, BIOASTER, Biofortis, Boehringer Ingelheim, CAPTECH Santé Nutrition, Charles River Laboratories, CNRS, EQT Life Sciences, EMBLEM Technology Transfer, Fund+, Eurofins, Genfit, GSK Glaxo Smith Kline, High-Tech Gründerfonds, INRAE Transfer, Ipsen, Jeito, Merck, MSD, Novo Holdings, Novo Nordisk, Pfizer, Réseau SATT, Roche, Sofinnova Partners, Spartners by Servier & Biolabs, Sterling Pharma Solutions, Thermo Fischer Scientific, Trinity College Dublin, Virbac, X’PROCHEM, Zoetis…
BioFIT is organised annually and alternates between Marseille, Lille and Strasbourg thanks to its organisers: Eurasanté, Clubster NHL, BioValley France and Eurobiomed.
Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within a European-wide scientific and medical site. Eurasanté also organises five international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic), MEDigIT (Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).
Clubster NHL is a competitiveness cluster and a network gathering 360 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.
Competitiveness cluster since 2005, BioValley France aims to federate, develop and promote the healthcare sector in the Grand Est region through innovation. The cluster is based on a dynamic network of companies, a leading academic and clinical research, as well as an integrated network of key stakeholders in innovation.
BioValley France supports its members in their R&D Innovation approach and gives them access to high value-added expertise, in a market approach. The Cluster contributes to the networking of the various actors and the creation of regional, national and international partnerships. Finally, BioValley France actively participates in the territory’s structuring projects, such as Nextmed, which aims to create a Medical Technologies campus in Strasbourg that hosts an entire ecosystem of excellence dedicated to the development of tomorrow’s health technologies.
Founded in 2009 by regional stakeholders, EUROBIOMED is the Life Science cluster from Southern France. We gather more than 420 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients. Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centers, start-ups and industrial success stories. Some of Eurobiomed main assets are the number of people involved, but also the quality of the network and trust that is established between its members, which reinforces the interactions and facilitates collaborations.BioFIT institutional partners